Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Asahi Kasei Life Science covers a broad range of bioprocess products and services
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
New research labs and process development services to enable next generation therapeutics
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
This innovative product eliminates two manufacturing steps and simplifies equipment setup
Subscribe To Our Newsletter & Stay Updated